Touchlight Genetics Limited

Six recombinant adeno-associated virus (rAAV) gene therapies have been commercially approved with a growing pipeline of \>550 under development globally. However, they exhibit prohibitive pricing and a long and expensive journey into the clinic partly due to inefficient manufacturing processes. Wider patient access requires increased productivity and effi...

Recent advancements in non-viral gene editing technologies offer precise genome engineering at significantly reduced costs and biosafety risks compared to viruses. CRISPR is a programmable genome targeting system, using DNA as a template for homology-directed repair (HDR) to introduce exogenous sequences for cell and gene therapy. ssDNA is more efficient,...

Toxic medicines are becoming a major focus of the pharmaceutical industry, as high potency products need minimal amounts to dose patients and so material requirements are low. However, the associated risks of working with these toxic products can make their development problematic, and traditional manufacturing routes are often unsuitable. This project wi...

Nanowires are simply very thin wires, but they have unusual and useful properties because of their size (1000x thinner than hair).In particular, the flow of small electric currents in a nanowire responds to the presence of chemicals, and quantum confinement allows for controllable photoluminescent properties.Many gases of relevance to industrial processes...

Gene therapy is becoming an increasingly important method of treatment for a variety of major unmet medical needs especially in the areas of inherited and rare diseases and diseases of the eye, conditions which are life threatening or significantly diminish quality of life. Adeno-associated virus (AAV) vectors are currently the delivery vehicle of choice ...

The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromics's proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and t...

To develop the cloning and expression of DNA metabolising enzymes to enhance the biosynthesis of novel DNA vaccine constructs devoid of contaminating bacterial DNA sequences.